Table 1.

Detailed information for senolytics and senomorphics

Drugs	Main Target	NCT#	COVID-19 and Anti-aging Evidence
Senolytics
Dasatinib	Tyrosine kinases	NCT04115059	A phase 2 trial assess the efficacy of dasatinib in treating moderate and severe COVID-19 cases
Quercetin	PI3K	NCT04578158	A phase 2 randomized, open-labelled and controlled study aimed to investigate the adjuvant benefits of Quercetin Phytosome in community-based subjects with confirmed SARS-CoV-2 infection
Fisetin	PI3K/AKT	NCT04771611	A phase 2 placebo-controlled pilot study in COVID-19 of fisetin to alleviate dysfunction and decrease complications in at-risk outpatients
ABT-263	Bcl-2 family	Not available	Not available
Cardiac glycosides	Na + /K + -ATPase	Not available	Not available
Senomorphics
Rapamycin	mTOR	NCT04409327	A phase 2 study to determine if RTB101 reduces the severity of COVID-19 in older adults residing in nursing homes
Metformin	NF-κB	NCT04604678	A phase 2 study into the use of metformin and LDN for patients with COVID-19
Aspirin	COX1, COX2	NCT04410328	A phase 3 study to explore the efficacy of Aggrenox (Dipyridamole ER 200 mg/ Aspirin 25 mg orally/enterally) in patients with SARS-CoV-2 infection with symptoms consistent with COVID-19
Resveratrol	t-PA-1	NCT05601180	An interventional, controlled clinical study to evaluate of the efficacy of Respicure® (resveratrol / quercetin) in the management of respiratory conditions including long COVID
Spermidine	TC45	NCT05421546	An interventional study to evaluate the efficacy of spermidine as a nutraceutical in enhancing vaccine responses, mitigating immune senescence, and reducing inflammaging among human volunteers aged over 65, either during or after vaccination against SARS-CoV-2 or influenza